CoChat
Sign Up
Cited by 131Fatty Acid Research and HealthAcute Myocardial Infarction ResearchNutritional Studies and Diet

Efficacy of n‐3 polyunsaturated fatty acids after myocardial infarction: Results of GISSI‐prevenzione trial

Marchioli, Roberto, Schweiger, Carlo, Tavazzi, Luigi, Valagussa, Franco·2001·Lipids
DOI 10.1007/s11745-001-0694-8
Open this paper in CoChat — free account

Abstract

Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio (GISSI)-Prevenzione was conceived as a population, pragmatic trial on patients with recent myocardial infarctions conducted in the framework of the Italian public health system. In GISSI-Prevenzione, patients were invited to follow Mediterranean dietary habits, and were treated with up-to-date preventive pharmacological interventions. Long-term n-3 PUFA (1 g daily) but not vitamin E (300 mg daily) was beneficial for death and for combined death, nonfatal myocardial infarction, and stroke. All the benefit, however, was attributable to the decrease in risk for overall, cardiovascular, cardiac, coronary, and sudden death. At variance with the orientation of a scientific scenario largely dominated by the "cholesterol-heart hypothesis," GISSI-Prevenzione results indicate n-3 PUFA (virtually devoid of any cholesterol-lowering effect) as a relevant pharmacological treatment for secondary prevention after myocardial infarction. As to the relevance and comparability of GISSI-Prevenzione results, up to 5.7 lives could be saved every 1000 patients with previous myocardial infarction treated with n-3 PUFA (1 g daily) per year. Such a result is comparable to that observed in the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial, where 5.2 lives could be saved per 1000 hypercholesterolemic, coronary heart disease patients treated with pravastatin for 1 yr. The choice of a relatively low-dose r…

Integrity signals

Registry

Crossref · 10.1007/s11745-001-0694-8

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GISSI-P began enrolling patients in 1993, before the availability of high-intensity statin therapy.

    “This trial began enrolling patients in 1993, before the availability of high-intensity statin therapy.17,27”

    From Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality (2025) · cites this paper as [27]

  • Contemporary high-intensity statin formulations achieve greater low-density lipoprotein-lowering effects and cardiovascular endpoint reduction than were used during the first mixed EPA/DHA trials, such as GISSI-P.

    “contemporary high-intensity statin formulations achieve greater low-density lipoprotein–lowering effects and cardiovascular endpoint reduction than were used during the first mixed EPA/DHA trials, such as GISSI-P.17,27,44”

    From Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality (2025) · cites this paper as [27]

Cited by

Sorted by citations

Authors
Marchioli, R., Schweiger, C., Tavazzi, L., & Valagussa, F.
Affiliations
  • Mario Negri Institute for Pharmacological Research (IT)
  • Ospedale di Passirana di Rho Milano Italy
  • Policlinico San Matteo Fondazione (IT)
  • Azienda Ospedaliera San Gerardo (IT)
Corresponding author
Marchioli, Roberto
ORCID
Tavazzi, Luigi
Venue
Lipids
Publisher
Wiley
Published
2001-01
Volume
36
Issue
S1
Pages
S119-26
ISSN
  • 0024-4201 (ISSN-L)
  • 1558-9307
DOI
10.1007/s11745-001-0694-8
OpenAlex
W2070156798
Cited by
131
References
0
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 8 · 2018: 7 · 2017: 5 · 2016: 1 · 2015: 7 · 2014: 4 · 2013: 6 · 2012: 16
FWCI
3.03
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Lipids (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
Keywords
omega-3 fatty acids, myocardial infarction, secondary prevention, vitamin E, Mediterranean diet, cardiovascular mortality, sudden cardiac death, pravastatin, LIPID trial, dietary recommendations
MeSH terms
Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Angiotensin-Converting Enzyme Inhibitors, Hypolipidemic Agents, Aspirin, Diet, Docosahexaenoic Acids, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Vitamin E, Eicosapentaenoic Acid, Fatty Acids, Omega-3, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review